Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 1.459 EUR 0.21%
Market Cap: 999.6m EUR

Wall Street
Price Targets

PHARM Price Targets Summary
Pharming Group NV

Wall Street analysts forecast PHARM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHARM is 2.009 EUR with a low forecast of 1.414 EUR and a high forecast of 2.573 EUR.

Lowest
Price Target
1.414 EUR
3% Downside
Average
Price Target
2.009 EUR
38% Upside
Highest
Price Target
2.573 EUR
76% Upside
Pharming Group NV Competitors:
Price Targets
4974
Takara Bio Inc
46% Upside
214450
PharmaResearch Co Ltd
98% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
29% Upside
ALKS
Alkermes Plc
57% Upside
FHTX
Foghorn Therapeutics Inc.
173% Upside
251120
Bio-FD&C Co Ltd
20% Upside
VYGR
Voyager Therapeutics Inc
257% Upside
4BB
4Basebio PLC
144% Upside

Revenue
Forecast

Revenue Estimate
Pharming Group NV

For the last 13 years the compound annual growth rate for Pharming Group NV's revenue is 42%. The projected CAGR for the next 3 years is 13%.

42%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Pharming Group NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-18%
Average Miss

Net Income
Forecast

Net Income Estimate
Pharming Group NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PHARM's stock price target?
Price Target
2.009 EUR

According to Wall Street analysts, the average 1-year price target for PHARM is 2.009 EUR with a low forecast of 1.414 EUR and a high forecast of 2.573 EUR.

What is Pharming Group NV's Revenue forecast?
Projected CAGR
13%

For the last 13 years the compound annual growth rate for Pharming Group NV's revenue is 42%. The projected CAGR for the next 3 years is 13%.

Back to Top